Lead regulatory counsel for private equity investment firm on its acquisition of California-based fertility practices.
Lead counsel for European-based digital therapeutics company on its market access strategy in the United States. Representation includes negotiating affiliation agreements with drug manufacturers and payers.
Lead compliance counsel for large long-term care company operating under a Corporate Integrity Agreement with OIG-HHS.
Representing several nonprofit health care systems on hospital-physician compensation structures and alignment, and compliance with reimbursement regulations.
Serves as outside regulatory and fraud and abuse counsel to publicly traded Fortune 500 health care and life science corporation.*
Lead counsel for private equity backed portfolio provider and its management company in a voluntary disclosure to the HHS-OIG.*
Lead regulatory counsel for private equity investment firm on its financing of a complex buyout and restructuring of a physician management and radiation oncology services company.*
Lead regulatory counsel to a private equity investment firm on its multi-billion dollar bid to take a publicly traded health care IT company private.*
Represented pharmaceutical manufacturer in restructuring of its corporate compliance program.*
Lead counsel for global pharmaceutical ingredient supplier and its wholly-owned subsidiaries in an investigation and subsequent settlement under the FCA concerning inflated average wholesale prices, kickbacks to physicians, and waivers of co-pay.*
Lead defense counsel for long term care company in two FCA matters, one of which settled after a protracted multi-year civil and criminal investigation, and another resulting in a declination by both the Department of Justice and respective State Attorney General’s Office.*
Lead counsel for a large pharmacy benefit manager in two separate investigations under the FCA, both of which were subsequently closed by DOJ without any further action.*
Lead counsel for regional health system resulting in a declination by DOJ of a qui tam alleging false claims based on provider-based billing and 340B.*
Represented several large not-for-profit health systems in various regulatory and fraud and abuse issues.*
Represented a hospice services entity in a complex post-sale dispute with a private-equity backed national hospice company. After buyer self-disclosed to OIG, and sued the seller in arbitration for the proposed settlement amount with OIG, Mr. Bewley persuaded OIG that its client was the party-of-interest and negotiated a resolution with OIG for almost $10 million less than originally proposed.*
Represented numerous entities operating under Corporate Integrity Agreements with HHS-OIG.*
*Denotes experience prior to joining Manatt.